Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:GRCL

Gracell Biotechnologies (GRCL) Stock Price, News & Analysis

Gracell Biotechnologies logo

About Gracell Biotechnologies Stock (NASDAQ:GRCL)

Key Stats

Today's Range
$10.25
$10.25
50-Day Range
$10.14
$10.35
52-Week Range
$1.40
$10.44
Volume
N/A
Average Volume
1.32 million shs
Market Capitalization
$744.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.06
Consensus Rating
Hold

Company Overview

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

GRCL Stock News Headlines

GRCL Mar 2024 10.000 call(CONTR
Gracell Biotechnologies Acquisition Completed
Is AI Hype Hiding the Big Picture?
Jeff Bezos has loaded up on a tiny company being called "the Next Nvidia." If you've never heard of what I call "QaaS" technology, you need to see this now.
Gracell Biotechnologies Acquisition Completed
Gracell Biotechnologies Inc. (GRCL)
See More Headlines

GRCL Stock Analysis - Frequently Asked Questions

Gracell Biotechnologies Inc. (NASDAQ:GRCL) announced its earnings results on Sunday, November, 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.18. The company earned $0.06 million during the quarter.

Gracell Biotechnologies (GRCL) raised $150 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gracell Biotechnologies investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Adobe (ADBE).

Company Calendar

Last Earnings
11/14/2021
Today
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:GRCL
Fax
N/A
Employees
314
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.06
High Stock Price Target
$10.25
Low Stock Price Target
$10.00
Potential Upside/Downside
-1.8%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-88,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$60,000.00
Price / Sales
12,415.83
Book Value
$2.95 per share

Miscellaneous

Free Float
52,328,000
Market Cap
$744.95 million
Optionable
Optionable
Beta
-0.33
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:GRCL) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners